Please login to the form below

Not currently logged in
Email:
Password:

King Pharmaceuticals

This page shows the latest King Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Pfizer and Teva abuse-resistant painkillers

FDA panel backs Pfizer and Teva abuse-resistant painkillers

The company secured rights to Troxyca ER (also known as ALO-02) when it acquired King Pharmaceuticals in 2010 for $3.6bn.

Latest news

  • Opioid analgesics

    The initial development of this immediate-release tamper-resistant formulation, formally known as Acurox, was under collaboration with Acura and King Pharmaceuticals. ... As part of the research programme initiated by King Pharmaceuticals (now Pfizer)

  • Burton Paul appointed to 1HQ’s health division

    Paul brings more than 15 years experience in managing projects and clients across a wide range of sectors including FMCG and pharmaceuticals. ... His work includes brand delivery for some of the biggest names in the sector, most notably: Adcock Ingram,

  • Lipitor losses affect Pfizer's Q2 sales

    Sales were aided by the purchase of King Pharmaceuticals, with Pfizer gaining an extra $357m in sales.

  • FDA approves Pfizer's pain drug

    Oxecta was originally developed by King Pharmaceuticals. Pfizer acquired the drug when it purchased King in late 2010.

  • Survival strategy

    Marketed products. The M&A strategy in 2010 was reflected in Pfizer's acquisition of King Pharmaceuticals for $3.6bn announced in October and Astellas' acquisition of OSI Pharmaceuticals for $4bn ... Nevertheless there were a few deals in 2010, such as

More from news
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics